Claims for Patent: 9,339,551
✉ Email this page to a colleague
Summary for Patent: 9,339,551
Title: | Diclofenac topical formulation |
Abstract: | The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis. |
Inventor(s): | Kisak; Ed (San Diego, CA), Singh; Jagat (Toronto, CA) |
Assignee: | HZNP Limited (Pembroke, BM) |
Application Number: | 14/705,593 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,339,551 |
Patent Claims: |
1. A method for treating pain, said method comprising: administering a formulation to a patient in need thereof, wherein the formulation comprises: 2% w/w of diclofenac
sodium; 30-60% w/w of DMSO; 1-15% w/w of propylene glycol; 1-30% w/w of ethanol; water; a viscosity of 500-5000 centipoise; and at least one thickening agent selected from the group consisting of a cellulose polymer, a carbomer polymer, a carbomer
derivative, a cellulose derivative, and mixtures thereof, wherein the administration of the formulation is twice daily, to thereby effectively treat pain.
2. The method of claim 1, wherein the concentration of DMSO is about 40% to about 50% w/w. 3. The method of claim 2, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between. 4. The method of claim 1, wherein the concentration of ethanol is present at 23-29% w/w. 5. The method of claim 1, wherein the at least one thickening agent is selected from the group consisting of a carbomer polymer, a carbomer derivative and mixtures thereof. 6. The method of claim 5, wherein the at least one thickening agent is selected from the group consisting of carbopol 971, carbopol 981, carbopol 941, carbopol 1342 and ultrez 10. 7. The method of claim 6, wherein glycerine is present. 8. The method of claim 1, wherein the at least one thickening agent is selected from the group consisting of a cellulose polymer, a cellulose derivative, and mixtures thereof. 9. The method of claim 8, wherein the at least one thickening agent is hydroxypropyl cellulose. 10. The method of claim 1, wherein the formulation comprises: 40-50% w/w of DMSO; 23-29% w/w of ethanol; and 10-12% w/w of propylene glycol. 11. The method of claim 10, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between. 12. The method of claim 1, wherein the formulation has improved absorption on a per dose basis compared to a comparative liquid composition. 13. The method of claim 1, wherein the pain is due to osteoarthritis. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.